On February 18, 2026, Sunshine Biopharma Inc. obtained shareholder consent for a potential reverse stock split of up to 1-for-10, with the CEO holding about 96% of voting power. The final ratio will be decided by the board at its discretion, effective 20 days post notification to stockholders.